Correction: CytRx FDA letter
- On 4:33 pm EDT, Wednesday September 9, 2009
LOS ANGELES (AP) -- In a Sept. 8 story about CytRx Corp.'s response to a Food and Drug Administration letter, The Associated Press reported erroneously that CytRx said the FDA requested more information on a trial of arimoclomol. The letter provided a framework for a revised protocol for human testing to resume, but did not include a request for more information.
Related Headlines
- CytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Soft Tissue Sarcomas - Business Wire
- Pending Key Developments Ahead for CytRx Corporation (NASDAQ: CYTR) - Marketwire
- CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer - Business Wire
- CYTRX CORP Financials - EDGAR Online Financials
- CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - EDGAR Online
Related Blog Headlines
- CytRx Announces First of Two Positive Developments Ahead - at Seeking Alpha
- CytRx Corporation: Key Developments Ahead - at Seeking Alpha
- CytRx: Technical Breakout Imminent - at Seeking Alpha
Sponsored Links
-
Trade Stocks? Try Currency Trading
Trade in a highly trending market 24-hrs a day, 5.5 days a week. GFT. -
Earn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
-
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today. -
Super Cheap Car Insurance
Get Discount Car Insurance Quotes Online – Rates from $15 / Month.
Tech Ticker Recent Posts
Add Alert Copyright © 2009 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten, or redistributed without the prior written authority of The Associated Press.